Novo Nordisk in pact with Septerna for oral obesity drugs

1 month ago 4

• Healthcare
• On the Move

rafal_olechowski

Septerna (NASDAQ:SEPN) climbed ~63% in the premarket on Wednesday after the Wegovy maker Novo Nordisk (NVO) agreed to jointly develop and commercialize oral small-molecule drugs for obesity and other cardiometabolic diseases with the company in

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Novo Nordisk in pact with Septerna for oral obesity drugs